I rise this evening with great concern about a recent development that occurred yesterday here on the Hill. In the other body, the failure to close debate on medical liability reform, the most important legislation that this body passed in March, was to address this crisis; and now that reform is in danger. The House passed H.R. 5 to control unsustainable medical liability premium increases and to preserve patient access to important medical specialists. Based on a 1975 California law, the Medical Injury Compensation Reform Act of 1975, that has held down premium increases in that State, H.R. 5 would place a cap on noneconomic damages in medical liability cases. This bill would not limit access to the courthouse. This bill would not limit damages to those who have been injured by negligent actions. This bill would not reward bad doctors. This bill would not protect HMOs. This bill will increase access to important specialists such as neurosurgeons, perinatologists, and trauma surgeons. This bill will return sanity to a legal system that currently resembles a Las Vegas gaming device.
Michael Burgess: “I rise this evening with great concern about a recent development that occurred yesterday here on the Hill. In the other…”
Editor's note · Context
Addressing concerns over medical liability reform and its impact on healthcare access.
Share
More from Michael Burgess
I reserve the balance of my time. Mr. McGOVERN. Madam Speaker, may I inquire as to how many speakers the gentleman has remaining?
I am prepared for the gentleman to close. Mr. McGOVERN. Mr. Speaker, I yield myself the balance of my time to close. Mr. Speaker, let us talk about priorities. My Republican colleagues have theirs all screwed up, and I am being really kind…
For the purpose of debate only, I yield the customary 30 minutes to the gentleman from Massachusetts (Mr. McGovern), pending which I yield myself such time as I may consume. During consideration of this resolution, all time yielded is for…
I thank Dr. Bucshon from Indiana for yielding me the time on such an important reauthorization that we are undertaking today. Mr. Speaker, 2018 was the last authorization for sickle cell research. Prior to that, it had been part of the…





